Real‐world comparative effectiveness of adalimumab, etanercept and methotrexate: a Swedish register analysis

Background The advent of biosimilars may render etanercept (ETN) and adalimumab (ADA) viable alternatives to methotrexate (MTX) as first‐line systemics in psoriasis. However, real‐world relative effectiveness data comparing ADA and ETN to MTX are limited. Objective To estimate the relative effective...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the European Academy of Dermatology and Venereology 2020-03, Vol.34 (3), p.525-532
Main Authors: Svedbom, A., Ståhle, M.
Format: Article
Language:English
Subjects:
Adalimumab - therapeutic use
Adult
Etanercept - therapeutic use
Female
Humans
Male
Medicin och hälsovetenskap
Methotrexate - therapeutic use
Middle Aged
Prospective Studies
Psoriasis - drug therapy
Registries
Sweden
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The advent of biosimilars may render etanercept (ETN) and adalimumab (ADA) viable alternatives to methotrexate (MTX) as first‐line systemics in psoriasis. However, real‐world relative effectiveness data comparing ADA and ETN to MTX are limited. Objective To estimate the relative effectiveness of ADA and ETN compared to MTX. Methods We analysed data from DermaReg, a regional register in Stockholm, Sweden, to estimate drug survival and mean Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) during maintenance treatment. Results A total of 524 patients initiated 727 treatment episodes with ADA, ETN or MTX. After adjusting for confounders, patients treated with ADA had better drug survival (HR: 0.67; P = 0.003), lower mean PASI (−2.0; P 
ISSN:0926-9959
1468-3083
1468-3083
DOI:10.1111/jdv.15978